Psychedelics researchers and investors are still reeling from last week’s no vote for MDMA by a panel of advisers to the FDA.
Clinical trials of MDMA have been promising, but concerns have emerged about the quality of the research. A June hearing scheduled by the Food and Drug Administration is likely to address them.